20190916 PR ANSM TG4050 EN
Category: 2019
Transgene Announces Upcoming Investor Meetings
20190829 PR financial Agenda
Transgene Provides an Update after the Interim Futility Analysis of the PHOCUS Study of Pexa-Vec in Liver Cancer
20190807 – Transgene Update EN
Transgene Provides Update on PHOCUS Study of Pexa-Vec in Liver Cancer Following Planned Interim Futility Analysis
20190802 PHOCUS Interim Analysis US
Transgene Receives MHRA Approval for a Clinical Trial of TG6002, a Next-generation Oncolytic Virus, Administered by Intrahepatic Artery Infusion in Patients with Colorectal Cancer with Liver Metastases
20190718 – TRANSGENE PR MHRA TG6002
Transgene Receives MHRA Approval for Lead myvac® Individualized Immunotherapy, TG4050, to Commence Clinical Development in HPV Negative Head and Neck Cancers in the UK
20190710 PR MHRA TG4050 EN
Success of Transgene’s €48.7 Million Rights Issue
http://finance.transgene.fr/en/launch.php
Transgene Announces the Launch of a Rights Issue
http://finance.transgene.fr/en/launch.php
Peer-reviewed publications confirm the potential of Transgene’s TG4001 and TG6002
20190605 Transgene publi TG4001 TG6002 EN
Last Patient Enrolled in the Phase 2 Trial with Transgene’s TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Advanced Lung Cancer (NSCLC)
20190527-PR-Last-patient-TG4010-1L-EN